Skip to main content
. 2014 Dec 26;17(4):308–313. doi: 10.4048/jbc.2014.17.4.308

Figure 1.

Figure 1

Flow sheet of questions on patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancers; panels were asked the 1st line treatment to 4th line treatment in sequence with (line) or without (dotted line) consideration of practical issues, showing T-DM 1, if practical, commanded 100% agreement at each sequence.